{
  "symbol": "REGN",
  "year": 2024,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.2085,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.445
  },
  "top_positive": [
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2024 2023 2024 2023 EYLEA 8 mg and EYLEA net product sales outside the United States $ 907.8 $ 886.3 $ 1,757.2 $ 1,733.4 Regeneron's share of collaboration profit from sales outside the United States $ 369.0 $ 363.5 $ 719.5 $ 710.4 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (16.0) (14.0) (32.6) (29.3) Regeneron's share of profits $ 353.0 $ 349.5 $ 686.9 $ 681.1 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% 39% 39% 38 Table of Contents Roche Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2024 2023 2024 2023 Global gross profit payment from Roche in connection with sales of Ronapreve $ 0.4 $ \u2014 $ 0.9 $ 222.2 Other \u2014 (3.8) \u2014 (3.8) Total Roche collaboration revenue $ 0.4 $ (3.8) $ 0.9 $ 218.4 Roche distributes and records net product sale\n positively impacted, compared to the U.S.",
      "score": 0.9846
    },
    {
      "sent": "37 Table of Contents Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2024 2023 2024 2023 Dupixent and Kevzara net product sales $ 3,666.1 $ 2,888.9 $ 6,837.0 $ 5,452.4 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,149.2 $ 857.8 $ 2,075.1 $ 1,569.2 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (160.9) (106.7) (282.8) (181.6) Regeneron's share of profits $ 988.3 $ 751.1 $ 1,792.3 $ 1,387.6 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 27% 26% 26% 25% The increase in our share of profits for the three and six months ended June\u00a030, 2024, compared to the same periods in 2023, was driven by higher profits associated with Dupixent sales.",
      "score": 0.9792
    },
    {
      "sent": "37 Table of Contents Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2024 2023 2024 2023 Dupixent and Kevzara net product sales $ 3,666.1 $ 2,888.9 $ 6,837.0 $ 5,452.4 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,149.2 $ 857.8 $ 2,075.1 $ 1,569.2 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (160.9) (106.7) (282.8) (181.6) Regeneron's share of profits $ 988.3 $ 751.1 $ 1,792.3 $ 1,387.6 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 27% 26% 26% 25% The increase in our share of profits for the three and six months ended June\u00a030, 2024, compared to the same periods in 2023, was driven by higher profits associated with Dupixent sales.",
      "score": 0.9792
    }
  ],
  "top_negative": [
    {
      "sent": "Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.",
      "score": -0.9531
    },
    {
      "sent": "Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions.",
      "score": -0.9371
    }
  ],
  "forward_snippets": [
    "dates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 the costs of developing, producing, and selling products or unanticipated expenses; \u2022 our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "(a) In collaboration with Bayer outside \nng, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 the costs of developing, producing, and selling products or unanticipated expenses; \u2022 our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "(b) In col\nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "We believe the information in the table is useful to investors as it demonstrates our pipeline productivity and our ability to innovate, discover, and develop new products, and bring those products to market either alone or based on contractual arrangements with other parties, which has a direct impact on our results of operations and financial condition.",
    "We believe the information in the table is useful to investors as it demonstrates our pipeline productivity and our ability to innovate, discover, and develop new products, and bring those products to market either alone or based on contractual arrangements with other parties, which has a direct impact on our results of operations and financial condition."
  ]
}